Diabetes Dialogue: Diabetes Tech Updates in October 2024

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

This episode spotlights news in diabetes technology from the latter half of October 2024. In the episode, hosts breakdown updates from multiple companies related to continuous glucose monitoring and insulin delivery. A brief overview of announcements covered in the episode by hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, can be found below:

Abbott's FreeStyle Libre 3: On October 30, 2024, Beta Bionics Inc announced the integration of the iLet Bionic Pancreas with Abbott’s FreeStyle Libre 3 Plus sensor. According to hosts, the new compatibility broadens choice for patients and offering flexibility in CGM usage. Additionally, this sensor has also been approved for use during MRI and CT scans, eliminating the need to remove the device, which adds convenience for patients requiring frequent imaging.¹

Integration with Tidepool: On October 28, 2024, Tidepool announced a new data integration with Abbott. With this integration, the Libre 3 now connects with Tidepool, allowing data from multiple CGMs to be consolidated in a single platform, streamlining data review for clinicians and patients and reducing training requirements.²

Omnipod 5 for iOS: on October 29, 2024, Insulet Corporation announced the full market release of its Omnipod 5 App for iPhones in the US. Now available for iPhone users (using Dexcom G6), the update allows features like preset meal settings, a valuable tool for patients who use flexible carb counting approaches.³

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References:

1. Beta Bionics. Beta bionics announces launch of the Ilet Bionic Pancreas with Abbott’s Freestyle Libre 3 Plus Sensor. Beta Bionics. October 29, 2024. Accessed November 11, 2024. https://www.betabionics.com/beta-bionics-announces-launch-of-the-ilet-bionic-pancreas-with-abbotts-freestyle-libre-3-plus-sensor/.
2. Tidepool. Tidepool will integrate with Abbott’s Freestyle Libre portfolio for seamless cloud-to-cloud data. Business Wire. October 28, 2024. Accessed November 11, 2024. https://www.businesswire.com/news/home/20241024402862/en/Tidepool-Will-Integrate-With-Abbott%E2%80%99s-FreeStyle-Libre-Portfolio-for-Seamless-Cloud-to-Cloud-Data.
3. Insulet Corporation. Omnipod® 5 app for iPhone® now fully available in the United States. Business Wire. October 29, 2024. Accessed November 11, 2024. https://www.businesswire.com/news/home/20241029838744/en/Omnipod%C2%AE-5-App-for-iPhone%C2%AE-Now-Fully-Available-in-the-United-States.